Eurofirst News: Eurofirst 100, Eurofirst 250, and Eurofirst 500 investment news
Eurofirst market news from the Euronext Stock Exchange: Eurofirst 100, Eurofirst 250, and Eurofirst 400

Latest Eurofirst News:

  • European carmakers higher on Nissan gains

  • IBEX adds 1.42 percent on session

  • France Telecom gains over 8.5 percent on results

  • Banks see declines in Europe

  • European equities lower on renewed subprime worries

  • IBEX gains again amid European equities declines

  • Truck maker Man up on bids rumors

  • IBEX gains almost 1 percent on session

  • European utilities gain again

  • European equities lower on session

  • Euronext news feed


    Recommended equities news sites

  • Euronext
  • Euro Watch
  • FTSE News
  • Tokyo Market News
  • NYSE News
  • Mortgages & Loans
  •  

    April 26, 2006

    Eurofirst up on day

    Filed under: Infineon, Capitalia, Roche, ABN Amro, STMicroelectronics, Siemens, Micronas Semiconductor, GBC Biotech

    The FTSE Eurofirst 300 added 0.26 percent on Wednesday to close at 1,390.96. Earnings news from several sectors helped the Eurofirst stay in positive territory.

    The semiconductor sector did well after Infineon reported its first profit in four quarters, on its automotive, industrial, and memory units. The German chipmaker was up 0.9 percent to €9.59. Elsewhere in the sector, Philips added 2.7 percent to €27.74, Siemens gained 2.3 percent to €79.75, and Micronas Semiconductor was up 1.2 percent to SFr33.40 despite downgrades from a number of brokers. Only STMicroelecctronics had a notable decline, losing 3.9 percent to €15.12 despite reporting better than anticipated quarterly results recently.

    The banking sector was mixed. Despite a 12.1 percent gain in net profits in the first quarter, ABN Amro was down 2.5 percent to €24.25. But Italian bank Capitalia was up 2.5 percent to €6.93 on merger rumors.

    A 15 percent rise in sales in the first quarter sent Swiss pharmaceuticals company Roche up 0.3 percent to SFr189.40. Much of the upswing in sales were on increased demand for Tamiflu and cancer drugs. Roche said it expects sales and earnings to rise even more as the year progresses. Elsewhere in the sector, GPC Biotech added 4.7 percent to €13.58 on a recommendation that it continue late-stage trials on a prostate cancer drug it is developing. The news brought an upgrade from “hold” to “buy” from West LB, which also raised the drugmaker’s target share price from €14.1 to €15.7.





    Latest Equities News:

  • Europe, US, most Asia markets lower on news, data

  • Equities decline globally on European debt concerns

  • Most global equities markets see declines on commodities prices

  • Europe, Asia markets mixed as Wall Street declines

  • European, US markets see gains as Asia markets remain mixed

  • European equities decline on lower credit rating for Greece

  • European equities markets gain, helped by US jobs report

  • Most global equities markets in decline

  • Europe, US, Asia markets all see declines

  • London markets see gains as most European markets retreat

  • Eurofirst News copyright 2012 Central Consultants